SHiELD will unlock the value of health data to European citizens and businesses by overcoming security and regulatory challenges that today prevent this data being exchanged with those who need it. This will make it possible to provide better health care to mobile citizens across European borders, and facilitate legitimate commercial uses of health data. The exchange of health data is already possible, but rarely happens in practice because it is hard to ensure that the combined ‘end-to-end’ system will be secure and comply with data protection laws. SHiELD will address these security and compliance challenges: • providing models and analysis tools for automated identification of end-to-end security risks and compliance issues and supporting privacy and ‘by design’; • defining an open and extensible data exchange architecture based on epSOS, able to support security measures to address these risks; • developing security mechanisms to deal with new and emerging risks, such as inference attacks on sensitive data, and risks from relatively unprotected mobile edge devices; • providing faster and more cost effective methods to verify and monitor compliance with multiple sets of applicable regulations; SHiELD case studies will address cross border scenarios in which a citizen needs health care while in one Member State, and care givers need access to their health data from different Member States. SHiELD will also consider how commercial providers of lifestyle services or wearable sensors may be involved in such data exchanges. SHiELD will thereby also create opportunities for using health data to create such products and services addressing the common European market. SHiELD will provide guidance in best practice to achieve end-to-end security and data protection compliance in health and health related applications. SHiELD will also feed into CEN-Cenelec and ETSI efforts to create EU standards for data protection by design in eHealth.

Multi-cloud applications refer to applications that dynamically can distribute their components over heterogeneous cloud resources and still hold the functional, business and non-functional properties (NFP) declared in their SLAs. The main objective of the DECIDE action is to provide a new generation of multi-cloud service-based software framework, enabling techniques and mechanisms to design, develop, and dynamically deploy multi-cloud aware applications in an ecosystem of reliable, interoperable, and legal compliant cloud services (DECIDE DevOps Framework). DECIDE will provide a set of architectural patterns and the needed tools (DECIDE ARCHITECT) to develop and operate (following the DevOps approach) multi-cloud aware applications that can be dynamically self-adapted to be re-deployed using the best combination of cloud services. DECIDE will also set up an ecosystem of trusted, interoperable and legally compliant cloud services (ACSmI-Advance Cloud Service meta-Intermediator) and the required mechanisms to register, discover, compose, use and assess them. One of the key innovations of the DECIDE solution relies on the development of the OPTIMUS deployment simulation tool capable of evaluating and optimizing the resulting non-functional characteristics from the user’s perspective considering a set of given cloud resources alternatives. The OPTIMUS deployment simulation tool, together with the continuous deployment supporting tool (DECIDE ADAPT), will provide the most adequate deployment application topology based on a set of users’ requirements automating the provisioning and selection of deployment scripts for multi-cloud applications. Three use cases will be conducted to validate. DECIDE will innovate by tackling with multi-cloud and non-functional aspects and moreover by incorporating a DevOps approach to the whole solution DECIDE outcomes, covering the specific needs of different multi-cloud applications for on-line gaming, e-Health and Network management.

The incidence of paediatric onset Inflammatory Bowel Diseases (PIBD) has risen dramatically in recent decades. Compared to adult forms, PIBD reflects a more severe disease, more often requiring aggressive treatment with immunomodulators, and thereby exposing children to a life-long risk of serious disease and treatment-related adverse events, such as infections and malignancies. Therefore, there is an urgent need to develop strategies which balance, on an individual basis, therapeutic effectiveness with risks of treatment. The overall goal of this proposal is to develop and validate a treatment algorithm for PIBD based on high or low risk predictors for early complicated or relapsing disease. This will improve effectiveness, while reducing treatment related risks and life-long complications due to uncontrolled disease progression. To attain this goal 3 specific aims are proposed under the umbrella of an international network, the "PIBD-net": 1) Development of an accessible and feasible risk-stratified treatment algorithm for new onset paediatric IBD on an existing inception cohort and validation in an independent cohort 2) Generation of a prospective large longterm real world inception cohort in a registry designed to analyze effectiveness and safety signals and correlate them to individual risk factors 3) Design and performance of a risk algorithm-based prospective large-scale multicenter randomized clinical trial (RCT) (stratification into high or low risk groups based on specific aim#1) in order to provide optimal personalized therapy : low risk azathioprine vx. methotrexate, high risk : methotrexate vx. adalimumab This project will translate into the first risk-stratified PIBD treatment algorithms allowing optimization of medical therapy while minimizing treatment-related risk (personalized medicine).